A fifty-dollar GLP-1 price for Medicare patients... unless you're sick in the wrong way. New to this story? Here's where it stands. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss. Then on July 1, a temporary pilot opened, the Medicare GLP-1 Bridge. Enrolled seniors get GLP-1 weight-loss drugs for a fifty-dollar monthly copay. Manufacturers supply them at a two-hundred-forty-five-dollar net monthly price, and Medicare covers about a hundred ninety-five per patient each month. Lilly CEO David Ricks says about seven hundred thousand seniors have started treatment under the rollout. And that's where GLP-1 Daily picks up. Who that fifty-dollar price skips, and which diagnoses land people on the wrong side of it. Then Amylyx books a Phase 3 slot at ObesityWeek, and we'll sort out what's actually new there. Silvara, start us off. This one's from Stock Titan:
The first late-breaking oral presentation will feature topline results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. This follows the Company’s announcement of positive topline results from LUCIDITY in August 2026.
Calendar item first. Amylyx says it'll present Phase 3 LUCIDITY at ObesityWeek, November 14 to 17 in Washington. And the results headlining that late-breaking slot? Same topline they already announced in August. So, nothing new on efficacy today. We got a time slot. Every efficacy word in that release is company-reported, it's 78 participants, and until there's a peer-reviewed paper, that's where it stays. And flip your mental model on this one. Avexitide is a GLP-1 receptor antagonist. It blocks the pathway most of our listeners are switching on every week, because after a Roux-en-Y bypass some people's GLP-1 response runs so hot their blood sugar crashes after meals. Which makes it a whole different patient population from the obesity-drug coverage fights. Small group, genuinely debilitating condition. And the second Amylyx presentation, the claims-data study, is separate work. Don't let a stock-news headline fold the two together. Sleep Review, with Jackie Fortiér:
His application to the pilot program was denied. La Marca has severe obstructive sleep apnea, one of several diagnoses that exclude patients from the Bridge program’s $50 monthly price. The notification didn’t say why he was rejected. He thinks that if he didn’t have that diagnosis, he would qualify due to his weight.
So, an update on the Medicare GLP-1 Bridge, the fifty-dollar-a-month pilot that opened July first. For me, this is the one worth sitting with today. It's August reporting from Jackie Fortiér that Sleep Review ran yesterday, so the rule's been around since summer. Here's the catch: certain diagnoses, severe sleep apnea among them, can disqualify you. Jeff La Marca. Sixty-eight, Basking Ridge, New Jersey. BMI forty-two, quadruple bypass, prediabetic. Couldn't swing Zepbound at seven-fifty a month. Applied to the Bridge, denied, and severe sleep apnea is on the exclusion list. Usually it's the diagnosis code that gets you in the door. Here the one on his chart is what keeps him out. And his notice didn't even say why, so... what does he appeal, exactly? He figures he'd have qualified on weight alone. So the sicker version of him gets the worse price. That's one man's account, but if you're on Medicare with a sleep apnea diagnosis, check with your prescriber and your Part D plan before you count on that fifty dollars. If you're finding GLP-1 Daily useful, please subscribe and leave us a review wherever you're listening. Reviews help other people find the show, and we're grateful you're here.
We're watching for Amylyx's Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia, presented at ObesityWeek on Sunday, November 15, at 8:30 a.m. ET.
Links to every story are in the show notes, so dig into whichever ones you'd like. That's GLP-1 Daily for today. Thanks for listening, and we'll be back tomorrow. This is a Lantern Podcast.